Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors
Program
Contacts

ViewPoints: Will Roche plot broader subcutaneous strategy for US market

03.04.2017

Earlier this week, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favour of Roche’s subcutaneous version of Rituxan. With the agency scheduled to make an approval decision by June 26, the signs are positive. Given the overwhelmingly positive nature of Wednesday’s AdCom, analysts think Roche may now look to develop subcutaneous versions of other key oncology brands for the US market, as it has done in Europe.

Source: firstwordpharma.com


Back to the list





Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34